Navigation Links
YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
Date:10/29/2009

e American Society for Therapeutic Radiology and Oncology's Annual Meeting on November 2, 2009 reporting on 48 month survival data in "BEST", a randomized 4-arm trial of nimotuzumab with radiation and chemoradiation with patients with locally advanced head and neck cancer. Scientific Session D: Head and Neck I - Advances in Targeted Biologic Therapy, 11:20a.m., Room W184.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 5,000 patients reported as having been treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differen
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... by researchers from the University of Leicester has ... unlocking the potential to create new materials using ... been published in the prestigious academic journal ... technique to examine in rich detail the structure ... containing an acetylene molecule and a single helium ...
(Date:7/25/2014)... 2014 The Conferee Networking committee is ... Conferee Networking. These two-hour sessions provide a unique networking ... resolve problems, discuss new techniques, or brainstorm new ideas ... a topic for consideration is August 31, 2014, and ... Conferee Networking committee will review the topics, and status ...
(Date:7/25/2014)... 25, 2014 At the request of ... a 60-day extension for the public comment period (Docket ... for Model Aircraft established by Congress as part of ... 60-day extension establishes the new deadline for comments as ... of Transportation/FAA notice published in the Federal Register on ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2FAA Grants Comment Extension at the Request of AMA 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3
... Nile Therapeutics,Inc. (OTC Bulletin Board: SPDU.OB), announced ... present at the Biotechnology Industry,Organization (BIO) Investor Forum ... Time at The Palace Hotel in San Francisco, ... and an update on its clinical,development programs, including ...
... Oct. 2 /PRNewswire/ - Respironics, Inc. (Nasdaq:,RESP) today ... outstanding shares,of Apollo Light Systems, Inc., a 20-year-old, ... therapy systems for melatonin suppression and,circadian rhythm sleep ... is located in American Fork, Utah and has ...
... 2 Monitorforhire.com, the,fastest source for hiring ... faster. The company has added a mobile ... immediately to work requests via,PDA or cell ... Freedman, president of monitorforhire.com says that adding ...
Cached Biology Technology:Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum 2Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum 3Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 2Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 3
(Date:7/27/2014)... and fungi can evade treatment by acquiring mutations in ... permanent mutations were once thought to be the only ... study has shown that microorganisms can use a temporary ... to gain the benefits of drug resistance without the ... a fungus called Mucor circinelloides, it is likely to ...
(Date:7/27/2014)... In an age of "big data," a single computer ... tasks must instead be distributed across a cluster of ... how Facebook and Google mine your web history to ... Netflix recommend your next favorite book or movie. But ... , New technologies for monitoring brain activity are generating ...
(Date:7/25/2014)... lived on the land now called California, and many ... of plants they used for food, fuel, tools, and ... desired habitat and natural resources. , Frank Lake, an ... will lead a field trip to the ... of America,s 99th Annual Meeting, in Sacramento, Cal. this ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... as we grow older, our bones become more brittle and ... of mass is a major reason for older bones fracturing ... on slowing down this loss. However, new research from scientists ... Laboratory (Berkeley Lab) shows that at microscopic dimensions, the age-related ...
... Winston-Salem, N.C. -- New research from Wake Forest ... electronics by developing, for the first time, an ... electrical properties, and inexpensive to produce. ... of physics at Wake Forest, her graduate students ...
... 2011 Neurotechnology , a provider ... the availability of SentiSight 3.0 , a Software ... version adds shape-based recognition and offers enhanced local-feature-based recognition ... also includes enhanced tracking of fast moving objects and ...
Cached Biology News:The brittleness of aging bones -- more than a loss of bone mass 2The brittleness of aging bones -- more than a loss of bone mass 3Flexible electronics hold promise for consumer applications 2SentiSight 3.0 Universal Object Recognition Technology Available Now From Neurotechnology 2SentiSight 3.0 Universal Object Recognition Technology Available Now From Neurotechnology 3SentiSight 3.0 Universal Object Recognition Technology Available Now From Neurotechnology 4
... AviTag E. coli Biotinylation Kit, Plasmid is designed ... E. coli expression kits. (Cat. No. 3 186 ... kit provides vectors for the easy introduction of ... expressed protein can be enzymatically mono-biotinylated by E. ...
... The ubiquitin-proteasome pathway is the major ... eukaryotic cells, where it catalyzes the ... and the rapid elimination of proteins ... 1998; Hochstrasser 1996). The critical protease ...
... technology enables sensitive, fast and specific detection ... Short hybridisation time ( ... chromosome spreads Multiplex capability Available ... Probes available with different labels. ...
... * Source rat ... T25 plated cells $550.00, * ... 120 population doublings, * This ... complete ,growth medium M55007-08 and ...
Biology Products: